Multi-pass Transmembrane Proteins and Technology Platforms

Category: *CDMO

Booth No: M1033

Characteristic

In order to develop effective therapeutic targeting these TPs, a full length and biologically relevant form of these proteins needs to be isolated. Particularly, multi-pass TPs are notoriously difficult to purify due to complex structures with multiple hydrophobic transmembrane regions and low expression level in host cells but have become highly sought-after disease target.
ACROBiosystems has specially set up multiple technology platforms to address the structural complexity of multi-pass TPs and meet the needs of different application. ACRO has developed a full range of full-length multi-pass TPs with stabilized structure and high activity including CD20, Claudin18.2, CD133, GPRC5D, CXCR4, CCR5 and CCR8 to facilitate drug development and mechanism studies.

Menu

Multi-pass Transmembrane Proteins and Technology Platforms

Characteristic

Other Products

Products you may be interested in

Highest Rated Products